Drug intelligence / Profile preview

SM5-1

Development stage: Preclinical
Lead developer: Humboldt-Universität zu Berlin
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SM5-1 is a humanized mouse monoclonal antibody that targets a membrane protein of approximately 230 kDa overexpressed in hepatocellular carcinoma (HCC), melanoma, and breast cancer. It is used for targeted therapy due to its ability to inhibit cell growth and induce apoptosis. SM5-1 has been conjugated with gold nanoparticles and other materials to enhance its antitumor efficacy in HCC treatment[1][3][5].

Targets

gB (Human cytomegalovirus glycoprotein B)CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)ED-B (Fibronectin extra domain B)

Beyond the preview

Go deeper on SM5-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM5-1.

Explore the full profile